TSX runs higher on rate cut expectations
In a challenging year for Hillevax (HLVX), the biopharmaceutical company’s stock has plummeted to a 52-week low, touching down at $1.52. With a market capitalization of just $78.26 million, the company faces significant headwinds despite maintaining a strong liquidity position with a current ratio of 10.84. This latest price level reflects a stark contrast to the more optimistic valuations the company has seen in the past. Over the past year, Hillevax has experienced a precipitous drop in its stock value, with a staggering 1-year change of -90.71%. Investors have watched with concern as the stock has struggled to regain its footing in a market that has been unforgiving to the biotech sector. The 52-week low serves as a sobering benchmark for Hillevax, marking a period of intense pressure and uncertainty for the company’s financial future. According to InvestingPro analysis, while the company holds more cash than debt, it’s quickly burning through its reserves, with an EBITDA of -$105.08 million. InvestingPro’s Fair Value analysis suggests the stock may be slightly undervalued at current levels, with additional insights available through the subscription service.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.